CB1 Capital is an investment manager that specializes in the supply chain of cannabinoid-based wellness solutions, products and therapies that address a wide range of unmet medical conditions, or have commercial use-cases. The endocannabinoid system (ECS) is the one of the most ubiquitous networks of receptors in the human body and a retrograde signaling system helping to homeostaticly regulate neurotransmission. Science is teaching us that by targeting the right receptors with the right cannabinoids, a multitude of wellness indications, applications, and potentially groundbreaking medical breakthroughs are not only plausible—but probable. We view cannabis through the lens of ten verticals that include biopharmaceuticals, industrial hemp & farming, extraction & nutraceuticals, compliant laboratories, cultivation & dispensaries, cosmetics & vanity, and pet foods & supplements. CB1 Capital does not touch the plant or move the plant across state lines; we buy, sell, and invest in securities of publicly traded companies only. This platform was set up to educate and inform; we believe this is the next generation of impact investing and our mission is to effect positive change through cannabinoid wellness. Integrity matters; CB1 Capital was built with the foundational constructs of honesty, trust and respect and our partners, employees and advisors are held to the highest standard of conduct and operational diligence.